Anzeige
Mehr »
Login
Dienstag, 31.01.2023 Börsentäglich über 12.000 News von 679 internationalen Medien
"Kaufen" - Breaking News und technische Exzellenz…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N951 ISIN: SE0010133785 Ticker-Symbol: AC6 
Frankfurt
30.01.23
13:44 Uhr
0,375 Euro
-0,010
-2,60 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ALZECURE PHARMA AB Chart 1 Jahr
5-Tage-Chart
ALZECURE PHARMA AB 5-Tage-Chart
ACCESSWIRE
265 Leser
Artikel bewerten:
(1)

AlzeCure Pharma: AlzeCure Presents at Aktiespararna and Carlsquare

STOCKHOLM, SE / ACCESSWIRE / November 14, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Aktiespararna's event Digitala Aktiekvällen on November 16, and at Carlsquare's investor day on November 17, where CEO Martin Jönsson will present the company's latest developments, including the planned rights issue. The presentations will be followed by a Q&A session.

Aktiespararna's Digitala Aktiekvällen
The presentation will be held in Swedish and live streamed via http://www.aktiespararna.se/tv/live and via Aktiespararna's YouTube-kanal.
When: November 16 at 18:00 CET
More information: https://www.aktiespararna.se/aktiviteter/digitala-aktiekvallen-16-november-2022

Carlsquare's investor day focused on Life science
The presentation will be held in English and live streamed via https://youtu.be/44-USPlfLGk.
When: November 17 at 10:00 CET
Where: Infront Direct Studios, Kungsgatan 33, 2 floor, Stockholm
More information: https://carlsquare.com/sv/events/carlsquare-bjuder-in-till-investerardag-pa-temat-life-science/

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative small molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug projects. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets other types of severe pain in conditions such as arthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase and is continually working on business development to find suitable solutions for license agreements with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se

Image Attachments

Martin Jönsson CEO AlzeCure Pharma

Attachments

AlzeCure presents at Aktiespararna and Carlsquare

SOURCE: AlzeCure Pharma

View source version on accesswire.com:
https://www.accesswire.com/725479/AlzeCure-Presents-at-Aktiespararna-and-Carlsquare

Gold-Geheimtipp 2023 - Diese Aktie sollten Sie kennen
Experten sind überzeugt: Goldaktien gehören in jedes Depot. Das war schon 2022 so und für 2023 wird es sogar im besonderen Maße gelten. In diesem kostenlosen Report stellt der Börsen-Profi Marcel Torney eine besonders aussichtsreiche Gold-Aktie vor. Sichern Sie sich jetzt die ausführliche Analyse. Kostenlos und unverbindlich.
ALZECURE PHARMA-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2022 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.